Beacon Investment Advisory Services Inc. Sells 11,804 Shares of Insulet Co. (NASDAQ:PODD)

Beacon Investment Advisory Services Inc. trimmed its holdings in Insulet Co. (NASDAQ:PODD) by 7.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 150,780 shares of the medical instruments supplier’s stock after selling 11,804 shares during the period. Insulet comprises about 1.7% of Beacon Investment Advisory Services Inc.’s investment portfolio, making the stock its 14th largest holding. Beacon Investment Advisory Services Inc.’s holdings in Insulet were worth $39,364,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of PODD. Blue Trust Inc. grew its stake in Insulet by 84.1% in the third quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier’s stock valued at $30,000 after purchasing an additional 58 shares in the last quarter. Venturi Wealth Management LLC raised its holdings in Insulet by 633.3% in the 3rd quarter. Venturi Wealth Management LLC now owns 154 shares of the medical instruments supplier’s stock valued at $36,000 after acquiring an additional 133 shares during the period. TD Private Client Wealth LLC lifted its position in Insulet by 32.6% during the third quarter. TD Private Client Wealth LLC now owns 228 shares of the medical instruments supplier’s stock worth $53,000 after acquiring an additional 56 shares during the last quarter. Friedenthal Financial bought a new stake in shares of Insulet during the fourth quarter worth approximately $57,000. Finally, Versant Capital Management Inc grew its position in shares of Insulet by 106.1% in the fourth quarter. Versant Capital Management Inc now owns 305 shares of the medical instruments supplier’s stock valued at $80,000 after purchasing an additional 157 shares during the last quarter.

Analysts Set New Price Targets

PODD has been the subject of several research reports. Citigroup lifted their price target on Insulet from $283.00 to $310.00 and gave the stock a “buy” rating in a report on Wednesday, December 11th. Sanford C. Bernstein assumed coverage on shares of Insulet in a research report on Wednesday, November 6th. They issued an “outperform” rating and a $300.00 target price for the company. Canaccord Genuity Group raised their price target on shares of Insulet from $269.00 to $304.00 and gave the stock a “buy” rating in a research report on Monday, December 9th. JPMorgan Chase & Co. boosted their price objective on shares of Insulet from $280.00 to $330.00 and gave the company an “overweight” rating in a report on Thursday, December 12th. Finally, Raymond James raised their target price on shares of Insulet from $213.00 to $260.00 and gave the stock an “outperform” rating in a report on Monday, October 14th. Three research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $272.81.

Insulet Stock Up 1.0 %

Shares of PODD opened at $278.89 on Thursday. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.80 and a current ratio of 3.68. Insulet Co. has a 52 week low of $160.19 and a 52 week high of $282.86. The stock has a market capitalization of $19.56 billion, a price-to-earnings ratio of 47.76, a PEG ratio of 3.47 and a beta of 1.22. The stock has a fifty day moving average of $266.52 and a 200-day moving average of $234.38.

Insulet (NASDAQ:PODD) last announced its quarterly earnings results on Thursday, November 7th. The medical instruments supplier reported $0.90 EPS for the quarter, beating analysts’ consensus estimates of $0.77 by $0.13. Insulet had a return on equity of 27.98% and a net margin of 21.22%. The firm had revenue of $543.90 million for the quarter, compared to analyst estimates of $518.50 million. During the same period last year, the firm posted $0.71 earnings per share. As a group, sell-side analysts anticipate that Insulet Co. will post 3.22 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, EVP Eric Benjamin sold 12,394 shares of the firm’s stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $280.00, for a total value of $3,470,320.00. Following the completion of the sale, the executive vice president now directly owns 11,383 shares in the company, valued at $3,187,240. This trade represents a 52.13 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CAO Lauren Budden sold 915 shares of the stock in a transaction that occurred on Tuesday, December 10th. The stock was sold at an average price of $275.62, for a total value of $252,192.30. Following the completion of the transaction, the chief accounting officer now owns 5,733 shares in the company, valued at approximately $1,580,129.46. The trade was a 13.76 % decrease in their position. The disclosure for this sale can be found here. 0.47% of the stock is owned by insiders.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.